A direct comparison of the efficacy of antihistamines in SAR and PAR: Randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - The Vienna Challenge Chamber (VCC)

Current Medical Research and Opinion

Volumn 20, Issue 6, 2004, Pages 891-902

  Stubner P ^a   Zieglmayer, R ^a   Horak, F ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Grass pollen; House dust mite; Levocetirizine; Loratadine; Perennial allergic rhinitis (PAR); Seasonal allergic rhinitis (SAR); Vienna Challenge Chamber

Indexed keywords

HOUSE DUST ALLERGEN; LEVOCETIRIZINE; LORATADINE; PLACEBO;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GRASS POLLEN; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; PERENNIAL RHINITIS; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; VIENNA CHALLENGE CHAMBER;

CETIRIZINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENVIRONMENTAL EXPOSURE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; PIPERAZINES; PLACEBOS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; SEASONS; TREATMENT OUTCOME;

EID: 3042684544     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003700     Document Type: Article

References (22)

1. Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc 2001;22:185-9
2. Heinrich J, Richter K, Fyre C, et al. European Community Respiratory Health Survey in Adults (ECRHS). Pneumologie 2002;56:297-303
3. Scadding GK. Clinical assessment of antihistamines in rhinitis. Clin Exp Allergy 1999;29:77-81
4. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000;55:116-34
5. Sakaguchi M, Inouye S, Yasueda H, et al. Measurement of allergens associated with dust mite allergy, II. Concentrations of airborne mite allergens (Der p I and Der p II) in the house. Int Arch Allergy Appl Immunol 1989;90:190-3
6. Horak F, Jager S. The Vienna Challenge Chamber - a new method of allergy exposure tests. Wien Klin Wochenschr 1987;99:509-10
7. Horak F, Jager S, Berger U, et al. Controlled exposure to mite allergen for a dose-finding of dimethindene maleate (DMM). Agents Actions 1994;41:C124-C126
8. Horak F, Berger UE, Menapace R, et al. Dose-dependent protection by azelastine eye drops against pollen-induced allergic conjunctivitis. A double-blind, placebo-controlled study. Arzneimittelforschung 1998;48:379-84
9. Horak F, Stubner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001;125:73-9
10. Horak F, Toth J, Marks B, et al. Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion. Allergy 1998;53;849-56
11. Horak F, Jager S, Berger U. Onset and duration of the effects of three antihistamines in current use - astemizole, loratadine and terfenadine forte - studied during prolonged, controlled allergen challenges in volunteers. J Int Med Res 1992;20:422-34
12. Horak F, Jager S, Toth J, Berger U. Efficacy and tolerability of astemizole-D and loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber. Arzneimittelforschung 1996;46:1077-81
13. Day JH, Briscoe M, Rafeiro E, Chapman P, Kramer B. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol 2001;87:474-81
14. Devalia JL, DeVos C, Hanotte F, Baltes E. A randomized, double-blind crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001;56:50-7
15. Wang DY, Hanotte F, DeVos C, Clement P. Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy 2001;56: 339-43
16. Leynadier F, Mees K, Arendt C, Pinelli ME. Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol Belg 2001;55:305-12
17. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998 May;101(5):638-45
18. Meltzer EO, Weller JD, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:617-26
19. Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994;48:617-37
20. Aerius scientific discussion. European Agency for the Evaluation of Pharmaceutical Products (EMEA), 2003 (available at: http://www.eudra.org/ humandocs/Humans/EPAR/aerius/ aerius.htm)
21. Horak F, Stubner P, Zieglmeyer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy. 2003;58(6):481-5
22. Horak F, Stubner UP, Zieglmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109(6):956-61